<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested interval between immune globulin or blood product and MMR or VZV vaccine*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested interval between immune globulin or blood product and MMR or VZV vaccine*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested interval between immune globulin or blood product and MMR or VZV vaccine*</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Product and indication<sup>¶</sup></td> <td class="subtitle1">Suggested interval (months)<sup>Δ</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="2">Immune globulin (IG) or monoclonal antibody administered intramuscularly</td> </tr> <tr> <td class="indent1">Hepatitis A prophylaxis (IG)</td> <td class="centered">6</td> </tr> <tr> <td class="indent1">Measles prophylaxis (IG) for nonpregnant, immunocompetent host (ie, standard measles prophylaxis)</td> <td class="centered">6</td> </tr> <tr> <td class="indent1">Tetanus IG (hyperimmune globulin)</td> <td class="centered">3</td> </tr> <tr> <td class="indent1">Hepatitis B IG (hyperimmune globulin)</td> <td class="centered">3</td> </tr> <tr> <td class="indent1">Rabies IG (hyperimmune globulin)</td> <td class="centered">4</td> </tr> <tr> <td class="indent1">Varicella prophylaxis (as Varizig; hyperimmune globulin)</td> <td class="centered">5</td> </tr> <tr> <td class="indent1">RSV prophylaxis (palivizumab [Synagis]) (monoclonal antibody)</td> <td class="centered">None</td> </tr> <tr> <td class="indent1">COVID-19 monoclonal antibody treatment or prophylaxis</td> <td class="centered">None</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Intravenous immune globulin (IVIG)</td> </tr> <tr> <td class="indent1" colspan="2">Replacement therapy (IVIG)</td> </tr> <tr> <td class="indent2">300 to 400 mg/kg</td> <td class="centered">8</td> </tr> <tr> <td class="indent1" colspan="2">For ITP (IVIG)</td> </tr> <tr> <td class="indent2">400 mg/kg</td> <td class="centered">8</td> </tr> <tr> <td class="indent2">1000 mg/kg</td> <td class="centered">10</td> </tr> <tr> <td class="indent1" colspan="2">For Kawasaki disease or multisystem inflammatory disease in children<sup>◊</sup> (IVIG)</td> </tr> <tr> <td class="indent2">2000 mg/kg</td> <td class="centered">11</td> </tr> <tr> <td class="indent1">Cytomegalovirus immune globulin</td> <td class="centered">6</td> </tr> <tr> <td class="indent1">Botulinum immune globulin (as BabyBIG)</td> <td class="centered">6</td> </tr> <tr> <td class="indent1">Measles prophylaxis (as IVIG)</td> <td class="centered">8</td> </tr> <tr> <td class="indent1">Varicella prophylaxis (as IVIG)</td> <td class="centered">8</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Blood products</td> </tr> <tr> <td class="indent1">Washed RBCs</td> <td class="centered">0</td> </tr> <tr> <td class="indent1">RBCs, adenine-saline added</td> <td class="centered">3</td> </tr> <tr> <td class="indent1">Packed RBCs</td> <td class="centered">6</td> </tr> <tr> <td class="indent1">Whole blood</td> <td class="centered">6</td> </tr> <tr> <td class="indent1">Plasma or platelet products</td> <td class="centered">7</td> </tr> </tbody></table></div><div class="graphic_lgnd">The information in this table does not apply to rubella-nonimmune women who received Rho(D) immune globulin or any other blood product during the last trimester of pregnancy or at delivery. Such women should receive MMR vaccine immediately after delivery and should be tested at least 3 months later for evidence of immunity to rubella and measles. It also does not apply to shingles vaccine. Refer to UpToDate content for details of MMR and VZV immunization and immunizations in patients with primary immunodeficiency.</div><div class="graphic_footnotes">MMR: measles, mumps, rubella; 
	VZV: varicella-zoster virus; 
	RSV: respiratory syncytial virus; 
	COVID-19: coronavirus disease 2019; 
	ITP: immune  thrombocytopenic purpura; 
	RBCs: red blood cells; 
	SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.<br/>
	
	* Immune globulins and plasma-containing blood products contain blood antibodies from the donor that may inhibit the response to MMR or VZV vaccines. The duration of inhibition ranges from 3 to 11 months and is related to the amount of antigen-specific antibody contained in the immune globulin or blood product.
	<ul>
<li>If the antibody-containing product is administered <strong>before</strong> the vaccine is scheduled, the vaccine should be delayed for the suggested interval. If a dose of MMR or VZV vaccine is administered after an antibody-containing product but at an interval shorter than the suggested interval, the vaccine dose should be repeated at the suggested interval unless an antibody response to the vaccine is documented.</li>
<li>If the antibody-containing product is necessary within 14 days <strong>after</strong> administration of MMR or VZV vaccine, the vaccine dose should be repeated after the suggested interval, unless an antibody response to the vaccine is documented.</li>
</ul>
	
	¶ For patients with indications other than those provided in the table, consultation with an expert in infectious diseases is suggested.<br/>
	
	Δ The suggested intervals may be shortened if exposure to measles is likely or has occurred (eg, during international travel or an outbreak).<br/>
<span class="lozenge">◊</span> Also called pediatric multisystem inflammatory syndrome, pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, pediatric hyperinflammatory syndrome, or pediatric hyperinflammatory shock.</div><div class="graphic_reference">Data from:
	<ol>
<li>American Academy of Pediatrics. Active immunization after receipt of immune globulin or other blood products. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.40.</li>
<li>Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-05" target="_blank">www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-05</a> (Accessed on June 5, 2021).</li>
</ol></div><div id="graphicVersion">Graphic 72640 Version 21.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
